Alimera Sciences to Present at Upcoming Investor Conferences

ATLANTA, GA / ACCESSWIRE / November 9, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will be presenting at the following investor conferences:

  • The 9th annual Craig-Hallum Alpha Select Conference in New York City on Thursday, November 15th, 2018.
  • The 11th Annual LD Micro Main Event at the Luxe Sunset in Bel-Air, CA at 11:30AM PT on Tuesday, December 4th, 2018.

A live webcast of the LD Micro presentation will be available on the Company website, www.alimerasciences.com, and remain available for a period of at least 90 days following the presentation. The Craig-Hallum presentation will not be publicly broadcast.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product and development portfolio. For more information, please visit www.alimerasciences.com.

CONTACT INFO:

For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
kbrazel@bellsouth.net

For investor inquiries:
Rich Cockrell
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital

SOURCE: Alimera Sciences, Inc.



View source version on accesswire.com:
https://www.accesswire.com/527588/Alimera-Sciences-to-Present-at-Upcoming-Investor-Conferences

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.